Preparation and evaluation of the effect of Fe₃O₄@piroctone olamine magnetic nanoparticles on matrix metalloproteinase‐2: A preliminary in vitro study

Abstract

In the present study, Fe3 O4 magnetic nanoparticles were synthesized by the coprecipitation of Fe(2+) and Fe(3+) ions and used as a nanocarrier for the production of piroctone-olamine-loaded Fe3 O4 nanoparticles (Fe3 O4 @PO NPs). The nanocrystalline structure of the prepared iron oxide species was confirmed by the X-ray diffraction spectroscopy method. Particle size distribution analysis showed that the size of Fe3 O4 @PO NPs was in the range of 5-55 nm. The magnetization curve of Fe3 O4 @PO NPs (with saturation magnetization of 28.2 emu/g) confirmed its ferromagnetic property. Loading of PO on the surface of Fe3 O4 NPs qualitatively verified by Fourier transform infrared spectrum obtained from Fe3 O4 @PO NPs. Cytotoxicity studies on the human fibrosarcoma cell line (HT-1080) revealed higher inhibitory effect of Fe3 O4 @PO NPs (50% cell death [IC50 ] of 8.1 µg/mL) as compared with Fe3 O4 NPs (IC50 of 117.1 µg/mL) and PO (IC50 of 71.2 µg/mL) alone. In the case of human normal fibroblast (Hs68), the viability percentage was found to be 75% in the presence of Fe3 O4 @PO NPs (120 µg/mL). Gelatin zymography showed 17.2% and 34.6% inhibition of matrix metalloproteinase-2 (MMP-2) in the presence of Fe3 O4 @PO and PO, respectively, at the same concentration of 40 µg/mL, whereas Fe3 O4 NPs did not inhibit MMP-2 at any concentration.

Preparation and Evaluation of the Antibacterial Effect of Magnetic Nanoparticles Containing Gentamicin: A Preliminary In vitro Study

“…The results exhibited that the addition of gentamicin on the surface of the MNPs using SA significantly increased the size of the G@SA-MNPs compared with MNPs ( p < 0.05). Such effects have been previously reported for MNPs coated with other compounds, such as piroctone olamine and umbelliprenin (23, 24). Furthermore, the surfaces of the MNPs were saturated with the adsorbed linear SA, and this induced both hydration forces and electrosteric stabilization due to the hydrophilic character of linear SA and the presence of charged polyelectrolyte loops, respectively.…”

“…Previously, Khorramizadeh et al (24) reported that each milligram of prepared umbelliprenin-coated MNPs contained almost 250 μg of umbelliprenin. Shakibaie et al reported the preparation of Fe 3 O 4 @piroctone olamine MNPs (without using polymers), which each 1 mg of the coated NPs contained 50 ± 1.3 μg of piroctone olamine (23). However, in the case of loading other antibiotics like amoxicillin on magnetic nanoparticles with Poly (lactide-co-glycolide) copolymer (PLGA) and Poly (lactide-co-glycolide)-polyethylene glycol copolymer (PLGA-PEG), the measured efficient entrapment was 90% and 48–52%, respectively (26).…”

Microstructure and Antibacterial Properties of Chitosan-Fe3O4-AgNP Nanocomposite

“…These results show that Fe 3 O 4 @Chitosan-AgNPs can be developed as nanomaterials that are antibacterial. Previous studies have reported that Fe 3 O 4 NPs at a concentration of 120 µg/mL had no cytotoxicity effect on normal line Hs68 cells with 89% viability [ 18 ]. Zhang et al have also reported that although magnetic Fe 3 O 4 nanoparticles at sizes 120 and 250 nm at various concentrations do not have significant toxicity in chicken macrophage cells (HD11).…”

Fe-MIL-101 exhibits selective cytotoxicity and inhibition of angiogenesis in ovarian cancer cells via downregulation of MMP

“…However, little evidence exists that nanomaterials themselves might possess intrinsic anticancer properties, and only a few nanoparticles’ intimate interactions with the tumour microenvironment were reported 13 14 15 16 17 . For example, Fe 3 O 4 nanoparticles coated with piroctone olamine 18 , fullerene-based nanomaterial Gd@C 82 (OH) 22 19 20 21 22 , hollow mesoporous carbon nanocapsules (HMCNs) 23 and polysaccharide-based hydrogels 24 have been found to exhibit inhibition of MMP activity. However, none have translated to clinical application due to the dose-limiting side effects following systemic administration of these pharmacological MMP inhibitors 24 .…”